scholarly journals Oral Effects and Early Implant Survival Results After Imatinib Discontinuation Therapy for Chronic Myelogenous Leukemia: A Case Report

2017 ◽  
Vol 7 (3) ◽  
pp. 115-120 ◽  
Author(s):  
Douglas R. Dixon ◽  
Alaa Yassin
Keyword(s):  
Case Report ◽  
Chronic Myelogenous Leukemia ◽  
Myelogenous Leukemia ◽  
Implant Survival

Congenital Juvenile Chronic Myelogenous Leukemia: Case Report and Review

PEDIATRICS ◽  
1984 ◽  
Vol 73 (3) ◽  
pp. 324-326
Author(s):  
Reese H. Clark ◽  
Leslie L. Taylor ◽  
Robert J. Wells
Keyword(s):  
Bone Marrow ◽  
Case Report ◽  
Chronic Myelogenous Leukemia ◽  
Peripheral Blood ◽  
Blast Crisis ◽  
Myelogenous Leukemia ◽  
Juvenile Form

The case of a patient with ecchymosis, hepatomegaly, leukocytosis, thrombocytopenia, and anemia at birth is presented. Throughout his course, thrombocytopenia, anemia, and leukocytosis without a marked increase in the number of blast forms in either peripheral blood or bone marrow persisted until the patient developed a blast crisis shortly before his death at age 4 months. This patient is the youngest reported to have the juvenile form of chronic myelogenous leukemia and the first that in the present era can be considered congenital in origin.

Multiple myeloma and chronic myelogenous leukemia: a case report with literature review

1993 ◽  
Vol 34 (3) ◽  
pp. 293 ◽  
Author(s):  
Philip J. Klenn ◽  
Bong H. Hyun ◽  
Young Hee Lee ◽  
Wen Yu Zheng
Keyword(s):  
Multiple Myeloma ◽  
Case Report ◽  
Literature Review ◽  
Chronic Myelogenous Leukemia ◽  
Myelogenous Leukemia

scholarly journals Concurrent JAK2-Positive Myeloproliferative Disorder and Chronic Myelogenous Leukemia: A Novel Entity? A Case Report With Review of the Literature

2019 ◽  
Vol 7 ◽  
pp. 232470961983232 ◽  
Author(s):  
Gilbert Bader ◽  
Bernard Dreiling
Keyword(s):  
Case Report ◽  
Chronic Myelogenous Leukemia ◽  
English Literature ◽  
Jak2 V617f ◽  
Patient Characteristics ◽  
Myeloproliferative Disorder ◽  
Myelogenous Leukemia ◽  
Jak2 V617f Mutation ◽  
Review Of The Literature ◽  
Shed Light

JAK2 V617F mutation and BCR-ABL translocation have been considered to be mutually exclusive. However, many cases where both hits coexisted have been reported. We have personally managed a case too. We believe this hybrid entity is underdiagnosed. Thus, we decided to shed light on this “double hit” disease to improve its diagnosis and optimize its treatment. We reviewed the English literature in PubMed since JAK2 discovery. We found 33 cases reported so far. We summarized patient characteristics and analyzed possible interactions between JAK2 and BCR-ABL clones.

Treatment of concurrent metastatic renal cell carcinoma and chronic myelogenous leukemia – easier said than done? A case report

2010 ◽  
Vol 17 (4) ◽  
pp. 436-439 ◽  
Author(s):  
Fouad Al-Najjar ◽  
Anthony Jarkowski
Keyword(s):  
Renal Cell Carcinoma ◽  
Case Report ◽  
Side Effects ◽  
Cell Carcinoma ◽  
Chronic Myelogenous Leukemia ◽  
Metastatic Renal Cell Carcinoma ◽  
Renal Cell ◽  
Myelogenous Leukemia ◽  
Treatment Regimens ◽  
Treatment Side Effects

Treating two active malignancies concurrently can be exceedingly difficult. Complications can occur from the different treatment regimens, especially if they share common targets, and the progressing diseases can make managing treatment side-effects even more challenging. We report a case of a patient with coexisting CML and mRCC who progressed on multiple lines of mRCC therapy while experiencing significant dose limiting side-effects.

Sign in / Sign up

Export Citation Format

Share Document